The reverse split is a mechanical adjustment with no fundamental impact. Monitor the stock price post-split for potential volatility and any subsequent Nasdaq compliance updates. The reduced share count may affect liquidity and option contract adjustments.
Price Chart
Executive Summary
Lakewood-Amedex Biotherapeutics filed a Certificate of Change to effect a 1-for-10 reverse stock split, reducing outstanding shares from approximately 17.5 million to 1.75 million. The split becomes effective June 19, 2026, with split-adjusted trading starting June 22, 2026. This is a routine capital structure adjustment, likely aimed at maintaining Nasdaq listing compliance, with no change to the company's fundamental value.
Key Facts
- 1-for-10 reverse stock split effective June 19, 2026; trading begins June 22, 2026
- Outstanding shares reduced from ~17,506,577 to ~1,750,789
- Authorized shares proportionately reduced to 12,500,000
- Common stock continues trading on Nasdaq under symbol LABT with new CUSIP 51255A201
- Board unanimously approved the split on June 1, 2026
Financial Impact
No financial impact; reverse split does not change market capitalization or enterprise value
Risk Factors
- Post-split price decline could trigger renewed delisting risk if the stock fails to maintain Nasdaq minimum bid price
- Fractional shares rounded up may cause minor dilution
- Adjusted warrant and option exercise prices could affect future dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-069512 |
| Document: ea029484501ex3-1.htm | 0001213900-26-069512 |
| Document: 0001213900-26-069512-index-headers.html | 0001213900-26-069512 |
| Document: 0001213900-26-069512-index.html | 0001213900-26-069512 |
| Document: 0001213900-26-069512.txt | 0001213900-26-069512 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | EFFECT | $1.67 $0.3100 | ▼ −81.44% | ▼ −79.96% | $0.2644 (−84.17%) |
Sep 18, 2026 5w ago | S-1 | $2.05 $0.5834 | ▲ +71.54% | ▲ +70.63% | $0.2644 (+87.10%) |
Jun 17, 2026 18w ago | 8-K | $0.6022 $0.1890 | ▼ −68.62% | ▼ −68.93% | $0.2644 (−56.09%) |
May 14, 2026 23w ago | EFFECT | $19.60 $7.70 | ▲ +60.71% | ▲ +59.86% | $0.2644 (+98.65%) |
May 6, 2026 24w ago | 3 | $33.00 $6.70 | ▼ −79.70% | ▼ −80.51% | $0.2644 (−99.20%) |
Apr 20, 2026 27w ago | EFFECT | — | awaiting T+20 | — | — |
Apr 1, 2026 29w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 11, 2026 32w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers